as of 02-20-2026 4:00pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 26.6M | IPO Year: | 2021 |
| Target Price: | $2.25 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | 26.77 |
| 52 Week Low/High: | $0.21 - $2.79 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.40 | Index: | N/A |
| Free Cash Flow: | -82391000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how IOBT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.